| Preface | |
| Introduction | |
| General Considerations | |
| Percutaneous Absorption and Conventional Penetration Enhancers | p. 3 |
| Lipid Flow Phenomena Between Liposomes, Lipoproteins and Cell Membranes; Applications in Drug Delivery | p. 11 |
| Basic Principles of Liposomes for Drug Use | p. 20 |
| Chemical Aspects | |
| Phospholipids as Basic Ingredients | p. 29 |
| Liposome Dermatics: Chemical Aspects of the Skin Lipid Approach | p. 38 |
| Ceramides for Liposomes | p. 44 |
| Liposome Phospholipids: Toxicological and Environmental Advantages | p. 57 |
| Physico-chemical Aspects | |
| Liposome Production: Historic Aspects | p. 69 |
| Rationale for the Production and Dermal Application of Lipid Vesicles | p. 82 |
| Liposome Production: The Ethanol Injection Technique and the Development of the First Approved Liposome Dermatic | p. 91 |
| Liposome Production: The Sizing-Up Technology Starting from Mixed Micelles and the Scaling-Up Procedure for the Topical Glucocorticoid Betamethasone Dipropionate and Betamethasone | p. 101 |
| Properties and Characterization of Pre-Liposome Systems | p. 110 |
| Technological Aspects | |
| Changes in the Structure of the Human Stratum Corneum Induced by Liposomes | p. 121 |
| Monitoring in vivo Skin Hydration by Liposomes Using Infrared Spectroscopy in Conjunction with Tape Stripping | p. 137 |
| Liposome Dermatics: Assessment of Long-Term Stability | p. 150 |
| Delivery of Liposome-Encapsulated Agents to Artificial Membranes | p. 167 |
| Topical Delivery of Liposomally Encapsulated Ingredients Evaluated by In Vitro Diffusion Studies | p. 172 |
| Pre-Clinical Aspects: Kinetics and Toxicology | |
| The Fate of Liposomes in Animal Skin | p. 185 |
| The Fate of Liposomes for Topical Use in Skin Tissue Culture | p. 195 |
| Liposomally Encapsulated Active Ingredients Penetrate Through the Follicle | p. 200 |
| Biodisposition of Liposome-Encapsulated Active Ingredients Applied on the Skin | p. 206 |
| Distribution of Liposome-Encapsulated Ingredients in Human Skin Ex Vivo | p. 215 |
| Liposomes as Safe Carriers of Drugs and Vaccines | p. 226 |
| Pre-Clinical Aspects: Dynamics | |
| Comedolytic Activity of a Liposomal Antiacne Drug in an Experimental Model | p. 235 |
| Topical Delivery of Liposomally Encapsulated Interferon Evaluated by in Vitro Diffusion Studies and in a Cutaneous Herpes Guinea Pig Model | p. 242 |
| Comparative Activity of a Liposomal and a Conventional Econazole Preparation for Topical Use According to a Guinea Pig Tinea Model | p. 251 |
| Liposome-Encapsulated Enzymes for DNA Repair | p. 258 |
| Patent and Regulatory Aspects | |
| General Remarks on Patent Matter | p. 273 |
| Liposome Determatics to Come According to the Patent Literature | p. 281 |
| Clinical Regulatory Aspects of Topical Liposomal Drugs with Special Consideration of Safety Aspects | p. 288 |
| Clinical Aspects | |
| Clinical Trial Protocols for Anti-Inflammatory and other Liposome Dermatics | p. 299 |
| Chemical Composition of Liposomes and Its Influence on the Humidity of Normal Skin | p. 308 |
| Influence of Various Topical Liposome Preparations With and Without Active Ingredients on the Cutaneous Blood Flow | p. 315 |
| Increased Activity and Tolerability of a Conventional Glucocorticoid in a Liposomal Form | p. 320 |
| Influence of Liposomal Encapsulation on the Activity of a Herbal Non-Steroidal Anti-Inflammatory Drug | p. 329 |
| Future Prospects | |
| Past, Present and Future of Liposome Cosmetics | p. 341 |
| Liposomes in Drug Delivery: Present and Future | p. 346 |
| Subject Index | p. 353 |
| Table of Contents provided by Blackwell. All Rights Reserved. |
